Safety Profile
TB-500 Side Effects: Frequency & Severity
TB-500 (thymosin beta-4 fragment) has a favorable preclinical safety profile. Human trials are limited to small Phase II populations.
Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.
Common side effects
1Injection site reactions
Mild erythema or discomfort at injection site.
Uncommon side effects
3Fatigue
Reported anecdotally in first weeks of use.
Headache
Typically mild and transient.
Flushing
Reported in early doses.
Rare side effects
2Allergic reactions
Hypersensitivity possible in susceptible individuals.
Nausea
Uncommon and typically mild.
Contraindications
- Known hypersensitivity
- Active malignancy (angiogenic concern)
- Pregnancy and lactation
Drug interactions
- Limited data
- Theoretical interaction with other tissue-healing or angiogenic agents
Special populations
Not evaluated in pregnancy, pediatrics, or elderly populations. Not FDA approved.
Overall safety summary
TB-500 has shown good tolerability in limited human trials and no serious toxicity in preclinical models. As with BPC-157, the angiogenic mechanism raises theoretical concerns for use in active malignancy.
TB-500 side effects: FAQ
Is TB-500 banned by WADA?
Yes — TB-500 is on the WADA Prohibited List as a growth factor and is prohibited at all times in competitive sport.